RecruitingNSCLC Stage IVNSCLC, Recurrent
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
Sponsor: University of Kansas Medical Center
You may qualify if…
- ✓ Participant or legal representative is able to provide written informed prior to performing any protocol-related procedures
- ✓ Is willing and able to comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study
- ✓ Men or women at least 18 years of age with histologically or cytologically confirmed non-small cell lung cancer
- ✓ Previous history of other than lung cancer is allowed if no active treatment for that cancer within 1 year
- ✓ Life expectancy of at least 6 months
- ✓ De novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR/ ALK/ ROS-1) that was previously treated with either PD-1 / PD-L1 or the combination of PD1/PDL1 and cytotoxic chemotherapy, no more than 2 systemic regimens for metastatic disease with measurable disease \*. Maintenance therapy will be considered part of the 1 regimen
- ✓ At least 1 measurable lesion
- ✓ PDL1 TPS score less than 1% or unknown: first-line must be PD1/PDL1 inhibitor in combination with chemotherapy
You may not qualify if…
- ✕ The presence of any other concurrent severe and/or uncontrolled medical condition that would, in the investigator or treating physician's judgement, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol
- ✕ Has received investigational agents within 14 days or 5 half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
- ✕ Has a known hypersensitivity to atezolizumab or pirfenidone
- ✕ Has active medical or psychiatric illness that would interfere with the study treatment
- ✕ Has uncontrolled diabetes
- ✕ Has any of the following cardiac diagnoses:
- ✕ Unstable angina Myocardial infarction within 6 months Uncontrolled congestive heart failure Left ventricular ejection fraction \< 35%
- ✕ Has a history of any Grade 3 or 4 toxicities to a prior checkpoint inhibitor treatment
Where it's recruiting
Kansas
Fairway · Kansas City
Source: ClinicalTrials.gov · NCT04467723 · last updated 2026-01-28